Contrast-induced acute kidney injury (CI-AKI) is one of the most common causes of AKI in clinical practice. CI-AKI has been found to be strongly associated with morbidity and mortality of the patients. Furthermore, CI-AKI may not be always reversible and it may be associated with the development of chronic kidney disease. Pathophysiology of CI-AKI is not exactly understood and there is no consensus on the preventive strategies. CI-AKI is an active research area thus clinicians should be updated periodically about this topic. In this review, we aimed to discuss the indications of contrastenhanced imaging, types of contrast media and their impact on nephrotoxicity, major pathophysiological mechanisms, risk factors and preventive strategies of CI-AKI and alternative non-contrast-enhanced imaging methods. 
INTRODUCTION
Medical imaging has become an important diagnostic and therapeutic tool in clinical medicine in the era of great technological advances. Contrast media (CM) are increasingly used for better imaging in a broad spectrum of areas such as diagnostic computed tomography (CT) and magnetic resonance imaging (MRI), procedures of interventional radiology and percutaneous transluminal coronary angioplasty (PTCA). There are several adverse effects of CM including nausea, vomiting, thyroid dys function and hypersensitivity reactions such as urticaria, laryngeal edema, bronchospasm, hypotension and ana phylactoid shock [1] . Contrastinduced acute kidney injury (CIAKI) is one of the most important adverse effects of CM. In the past, CI AKI was considered to be a mild state with asymptomatic and transient elevations in serum creatinine values however recent studies have demonstrated that both short term and longterm mortality rates have been found to be significantly higher in patients with CIAKI compared to patients without CIAKI [2] . Furthermore, a history of CIAKI may be associated with development of chronic kidney disease (CKD) and progression to end stage renal disease (ESRD) in long term [3, 4] . In this review, we aimed to discuss the indications of contrastenhanced imaging, types of CM and their impact on nephrotoxicity, major pathophysiological mechanism of CIAKI, risk factors and preventive strategies of CI AKI and alternative noncontrastenhanced imaging methods.
DEFINITION OF CM
CM is a chemical substance which is used to improve the image quality of various body parts, to differentiate pathological from healthy tissues and to better delineate vascular structures. CM may be used by the way of oral route, intravascular or also through other luminal organs however absorption and nephrotoxic effects of CM used other than intravascular route may be negligible. In this review, the effects of intravascular administration of CM will be discussed.
DEFINITION OF CI-AKI
Various definitions of CIAKI have been used in the literature. The most widely used definition is the increase in serum creatinine ≥ 0.5 mg/dL or 25% increase of serum creatinine from the baseline value at 48 h after CM administration. However timing of serum creatinine analysis after CMenhanced imaging is controversial. Measurement as early as 12 h after the procedure (% change of creatinine from baseline) was found to significantly predict CIAKI and furthermore it was associated with the development of renal damage after 30 d [5] . Serum cystatin C levels have also been evaluated as an early marker of CIAKI. In the study by Briguori et al [6] performed on CKD patients undergoing PTCA, increase of cystatin C levels ≥ 10% at 24 h after the procedure was found to reliably predict the patients with high risk of CIAKI.
EPIDEMIOLOGY OF CI-AKI
Incidence of CIAKI in patients undergoing elective, non emergent contrastenhanced CT has been found to be very low, < 1% [7] . In CKD patients, incidence of CIAKI after intravenous CM administration was found to be 4% [8] . However incidence of CIAKI following contrast enhanced CT performed in an emergency setting was found to be higher, > 10% which might reflect the underlying severe clinical status of the patient [9] . Critically ill patients seem to be much more vulnerable to CIAKI. In a study performed on critically ill patients without preexisting renal disease, serum creatinine levels were elevated ≥ 25% from the baseline in 18% of the patients after CMenhanced CT [10] . Incidence of CIAKI in patients undergoing PTCA with normal baseline renal function was reported to be < 3% [11] . However, the incidence of CIAKI was found to be as high as 40% in CKD patients undergoing PTCA [12, 13] .
NEPHROTOXICITY OF MRI CONTRAST

AGENTS
Until recently, MRI contrast agents also called gadolinium based contrast agents (GBCA) have been considered to be safe in terms of nephrotoxicity. However GBCA has also been reported to cause AKI especially at high doses used for angiography in patients with preexisting CKD and diabetic nephropathy [1416] . In an in vitro study, cytotoxicity of GBCA was compared to that of iodinated CM in renal tubular cells at angiographic concentrations and GBCA was not less cytotoxic compared with iomeprol [17] . In another study, urinary interleukin18 and Nacetylglucosaminidase levels were found to increase transiently after administration of GBCA in patients with normal renal function [18] . These results suggest that GBCA also induces cytotoxicity in renal tubular cells. Another important adverse effect of GBCA is the specific clinical entity called nephrogenic systemic fibrosis (NSF) which occurs especially in patients with CKD. NSF is a potentially mortal complication associated with GBCA. Recently, a relationship between previous gadolinium administrations and high signal intensity in the several parts of the brain has been suggested independent of renal function [19, 20] . Gadolinium concentration in tissue was found to be strongly associated with cumulative gadolinium dose [21] . Currently, clinical significance of gadolinium deposition in tissues is unclear, further studies are needed to clarify this issue.
In clinical practice, although GBCA are considered to be relatively safer than iodinated CM, risks of AKI, NSF and brain deposition should be kept in mind [14, 16] .
CLINICAL ISSUES NECESSITATING CM USE
It is important for clinicians to know the indications of contrastenhanced imaging to avoid unnecessary contrast administration and its related complications. 
TYPES OF IODINATED CM AND THEIR
IMPACT ON NEPHROTOXICITY
Type, osmolality, molecular structure and viscosity of CM are important determinants of nephrotoxicity asso ciated with these agents (Table 2) . Hyperosmolal CM (HOCM) was shown to more frequently cause CIAKI compared with lowosmolal CM (LOCM) [22] . However HOCM are no more used in clinical practice. There are controversial results in studies comparing isoosmolal CM (IOCM) and LOCM as seen in Table 3 . In most of these studies, no difference was found between IOCM and LOCM in terms of renal safety. Metaanalyses comparing IOCM and LCOM are presented in Table 4 . In the meta analysis by Reed et al [23] , iodixanol (IOCM) was found to be associated with a reduced risk of CIAKI compared to iohexol (LOCM) however risk of CIAKI was not significantly different between iodixanol and other LOCM. In a very recent metaanalysis by Eng et al [24] , a modest decrease in the risk of CIAKI was found with iodixanol (IOCM) when compared to other LOCM however no difference was found between the groups in terms of risk of renal replacement therapy, cardiovascular outcomes or death. Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommended to use LOCM or IOCM instead of HOCM however due to lack of reliable evidence, no recommendation was made about the preference of IOCM or LOCM [25] . IOCM has lower osmolality compared with LOCM, however since IOCM has dimeric structure, it has higher viscosity than that of monomeric LOCM. Viscosity rather than osmolality determines the resistance to blood flow, thus IOCM may impair renal medullary blood flow to a greater extent compared to LOCM [26] . Lack of clear superiority of IOCM over LOCM in terms of renal safety may be caused by higher viscosity of IOCM.
MAJOR PATHOPHYSIOLOGICAL
MECHANISMS OF CI-AKI
Exact pathophysiological mechanism of CIAKI is not known and includes complex cascades of events. Proposed mechanisms of CIAKI are presented in Table 5 . The most important elements of pathophysiological mechanism of CIAKI seem to be the medullary hypoxia due to CM induced medullary vasoconstriction [2729] and direct renal tubular cytoxicity [3033] . CMinduced vasoconstriction is not exactly understood but it is probably caused by an imbalance between vasoconstrictive (endothelin, adenosine) and vasodilatatory mediators (nitric oxide and prostocyclin) [28, 32, 34] . The contribution of oxidative stress seems to be an important and complementary event that further exacerbates CIAKI [32, 35, 36] . In normal physiological state, renal medullary blood flow and oxygen tension are relatively lower than those of the renal cortex. Furthermore, thick ascending limb located in the outer part of the renal medulla has a high rate of ion transport with increased oxygen consumption exacerbating the relative hypoxia of the renal medulla. The most susceptible part of the nephron to hypoxia is wellknown to be the renal medulla. CM is shown to decrase the oxygen tension of the renal medulla and simultaneously CM induced osmotic diuresis causes increased sodium delivery to thick ascending limb leading to increased oxygen demand [27, 37] . CM is known to cause direct mesangial and tubular cell toxicity. Proposed mechanisms of CMinduced cytotoxicity include oxidative stress, cellular energy failure, impaired cellular calcium homeostasis and increased apoptosis [33, 3840] . In the study by Peer et al [33] , iodinated CM at different concentrations was found to induce apoptosis in both mesangial and tubular cells. The relationship between hypoxia, oxidative stress and direct cytotoxicity is not wellunderstood in the context of CIAKI. Previously, a mismatch between the metabolic demands and the perfusion of renal medulla, in another words "relative hypoxia" was suggested to cause increased oxidative stress leading to further cytotoxicity [36] . However, recently, in the study by Liu et al [32] , CMinduced direct cytotoxicity has been shown to cause increased oxidative stress even in the absence of hypoxia. Oxidative stress seemed to be a consequence not a cause of renal tubular injury. Furthermore, in this study CM was found to increase tubuloglomerular feedback which might contribute to disturbances of renal perfusion and filtration [32] . It may suggested that direct cytotoxicity of CM may be the primary event that pull the trigger rather than hypoxia, hypoperfusion or oxidative stress in the pathophysiological mechanism of CIAKI.
Diagnosis and treatment of vascular diseases such as coronary artery disease, pulmonary thromboembolism, arteriovenous malformations, aneurysms, arterial dissections and thrombosis Diagnosis and staging of neoplastic diseases and mass lesions Diagnosis of inflammatory and infectious diseases such as multiple sclerosis, meningitis, pancreatitis, diverticulitis
Table 1 Common indications for contrast media use in medical imaging
Ozkok S et al . Contrast-induced acute kidney injury CM induced increase in blood and renal tubular viscosity may lead to resistance to blood flow and further exacerbate the medullary hypoxia [41] . Another important mechanism may be the mitochondrial dysfunction, especially ionic CM was found to impair the mitochondrial functions and membrane potentials in proximal tubular cells [42] .
RISK FACTORS FOR CI-AKI
Patients who are scheduled to have a contrast enhanced diagnostic or interventional procedure should be evaluated for risk factors of CIAKI (Table 6 ). Most important risk factors for CIAKI are preexisting CKD (GFR < 60 mL/min per 1.73 m 2 ) and diabetes mellitus which may have additive effects on each other. In a study performed on patients undergoing contrastenhanced CT, incidence of CIAKI was found to be higher in diabetic CKD patients compared with nondiabetic CKD patients [43] .
Impacts of the type of imaging procedure and administration route of CM on CI-AKI
Type of the contrastenhanced procedure seems to be an important determinant of CIAKI. As aforementioned in this review, risk of CIAKI with invasive PTCA seems to be higher compared to that of contrastenhanced CT. This difference of the risk of CIAKI between the two procedures may be caused by two reasons: (1) clinical status and comorbidities of the patients; and (2) administration route of the CM. Patients undergoing PTCA usually have significant ischemic heart disease and advanced atherosclerosis. During PTCA, significant hypotension may occur leading to ischemic nephropathy in addition to CI AKI. Another important adverse event that may occur with invasive angiographic procedures is the cholesterol embolization syndrome (CES) which is sometimes hard to differentiate from CIAKI. Administration route of the CM may also be important in the occurrence of CIAKI. For contrast enhanced CT, CM is given intravenously, however 
Results
Feldkamp et al [94] Normal GFR PTCA (intra-arterial)
Hardiek et al [95] Normal GFR, diabetic patients
≥ 25% increase in SCr days 1, 3 and 7
No difference
Aspelin et al [96] (NEPHRIC) CKD, diabetic
Peak increase in SCr day 0-3 Iso-osmolal safer than low-osmolal CM Jo et al [97] (RECOVER)
Increase in SCr ≥ 25% or ≥ 0.5 mg/dL within 2 d
Iso-osmolal safer than low-osmolal CM Solomon et al [98] [102] CKD CT (intravenous) Iodixanol (IOCM) vs Iopromide (LOCM)
Peak rise in SCr days 1-3 Iso-osmolal safer than low-osmolal CM Wessely et al [103] CKD PTCA (intra-arterial)
Peak increase in SCr No difference Table 3 Major studies comparing low-osmolal and iso-osmolal contrast media in terms of renal safety CM: Contrast media; CKD: Chronic kidney disease; LOCM: Low-osmolal contrast media; CT: Computed tomography; PTCA: Percutaneous transluminal coronary angioplasty.
Ozkok S et al . Contrast-induced acute kidney injury in PTCA, CM is given intraarterially. Risk of CIAKI has been found to be higher with intraarterial CM compared to intravenous CM administration especially when CM is used suprarenally [44, 45] . With suprarenal intraarterial administration of CM, peak CM concentration within the kidney was found to be higher [46] . In the metaanalysis by Dong et al [47] , risk of CIAKI with intraarterial iodixanol was found to be significantly lower when compared with intraarterial LOCM. However no difference was found between IOCM and LOCM in terms of renal safety when CM was used intravenously. Similarly, in another meta analysis by Heinrich et al [48] , iodixanol was found to be safer than iohexol in CKD patients undergoing a procedure with intraarterial CM administration. Iodixanol (IOCM) may be suggested to be a better choice for patients in the interventional cardiology setting [47] .
Volume of CM
Lower doses of CM (definitions of low dose are variable: < 30125 mL) were found to be less nephrotoxic [49, 50] . In a study by Manske et al [49] , low dose of CM was defined as < 5 mL/kg per serum creatinine. Recently, newer CT modalities have been developed using low tube voltage and low CM volume to reduce radiation exposure and the risk of CI-AKI without sacrificing image quality [5153] . However it should be kept in mind that even very low doses of CM may lead to CIAKI in patients with high risk factors.
RISK SCORING FOR CI-AKI
Several risk scoring systems have been developed to predict the CIAKI. In the study by Mehran et al [54] , CI AKI was defined as an increase ≥ 25% and/or ≥ 0.5 mg/dL in serum creatinine at 48 h after PCI and they proposed a CIAKI risk stratification score based on 8 readily available variables including (1) patientrelated features such as age > 75 years, diabetes mellitus, chronic congestive heart failure (CHF), acute pulmonary edema, hypotension, anemia, and CKD; (2) if total risk score is ≤ 5, risk of CIAKI is 7.5% and risk of Medullary vasoconstriction and hypoxia [27] [28] [29] Direct cytotoxicity to renal tubular cells [30] [31] [32] [33] Release of vasoconstrictive mediators: Endothelin, adenosine, angiotensin Ⅱ, vasopressin [28] Reduction of vasodilatatory mediators: Nitric oxide, prostocyclin [28, 32, 34] Increased oxidative stress [32, 35, 36] Impairment of tubulo-glomerular feedback [32] Increased blood and renal tubular viscosity [41] Impairment of mitochondrial function and mitochondrial membrane potential [42] 
Ozkok S et al . Contrast-induced acute kidney injury
Metaanalyses Baseline renal functions Procedure/administration route Compared drugs Results
McCullough et al [104] (16 trials)
Both normal GFR and CKD
PTCA (intra-arterial) Iodixanol (IOCM) vs various LOCM
Iodixanol safer than LOCM, e.p. in patients with CKD or CKD + diabetes mellitus Reed et al [23] (16 trials) Both normal GFR and CKD PTCA + CT (intra-arterial + intravenous)
Iodixanol (IOCM) vs various LOCM
Overall, no difference. However, iodixanol safer than ioxaglate and iohexol Heinrich et al [48] (25 trials) Both normal GFR and CKD PTCA + IV urography + CT (intra-arterial + intravenous)
Overall, no difference. However, iodixanol safer than iohexol in CKD patients when CM used via intra-arterial route From et al [105] (36 trials) Both normal GFR and CKD PTCA + CT (intra-arterial + intravenous)
Overall, no difference. Iodixanol safer than iohexol Eng et al [24] ( Table 4 Meta-analyses comparing iso-osmolal and low-osmolal contrast media in terms of renal safety dialysis is 0.04%. However risk of CIAKI is 57% and risk of dialysis is approximately 13% with a total risk score of ≥ 16. In conclusion, in this study, increasing total risk score was found to exponentially predict increased risk of CIAKI. Another simple risk scoring for CIAKI in patients undergoing PTCI is composed of age, creatinine and ejection fraction (ACEF score) which has been found to be an independent and useful predictor of CI-AKI defined as a rise in serum creatinine ≥ 0.5 mg/dL [55, 56] .
TREATMENT OF CI-AKI
There is no specific treatment for CIAKI. There is no evidence that any of the preventive strategies are helpful once the CIAKI develops. Similar to the management of other types of AKI, stabilization of hemodynamic para maters and maintenance of normal fluid and electrolyte balance is crucial. Thus, prevention may be the only treatment modality for CIAKI.
PREVENTION OF CI-AKI
Preventive strategies of CIAKI are presented in Table  7 . First things first, to prevent CIAKI, avoid unne cessary contrast administration which requires good communication between the clinician and the radiologist. 
Intravenous hydration
Various strategies and drugs have been tried to prevent CIAKI in the literature (Table 8) , however intravascular hydration seems to be the best preventive measure against CIAKI [5759] . In a prospective randomized study, hydration with isotonic (0.9% saline) and halfisotonic (0.45% sodium chloride plus 5% glucose) solutions were compared in terms of efficiency in prevention of CIAKI in patients undergoing coronary angioplasty. Hydration was performed before, during and after the procedure and total amount of hydration was approximately 2000 mL. In this study, isotonic hydration was found to be superior to halfisotonic hydration in the prevention of CIAKI [57] . In a study performed on patients undergoing nonemergency cardiac catheterization, saline hydration starting from 12 h before the procedure was compared to unrestricted oral fluid intake [59] . Patients in the first group received normal saline for 24 h (at a rate of 1 mL/kg per hour). Intravenous saline hydration was found to decrease the both incidence and severity of CIAKI. In contrast, in a very recent prospective, randomized, noninferiority study performed on CKD patients (eGFR: 3059 mL/min per 1.73 m 2 ) undergoing an elective procedure with CM, patients were randomly assigned to receive intravenous 0.9% NaCl or no prophylaxis [60] . No prophylaxis group was found to be noninferior to prophylaxis group and furthermore it was found to be costeffective. However, despite the results of this study, we still strongly recommend hydration especially in patients with high risk of CIAKI. Hypervolemia should be avoided during hydration of the patients. Monitorization of left ventricular end diastolic pressure was found to be a useful and effective way of guiding fluid replacement in a randomized controlled trial [61] . Further studies are needed to prove the efficacy of hydration in prevention of CIAKI.
Sodium bicarbonate
There is controversy about the efficacy of sodium bicarbonate to prevent CIAKI, several studies found Assess the risk of CI-AKI Assess the need of contrast-enhancement, avoid unnecessary contrast administration Avoid concomitant use of other nephrotoxic drugs Hydrate the patient with isotonic saline and/or sodium bicarbonate before and after the procedure N-acetyl-cysteine 1200 mg orally twice daily Prefer iso-osmolal or hypo-osmolal CM Use minimum amount of CM Check renal functions within 1 wk of the procedure CI-AKI: Contrast-induced acute kidney injury; CM: Contrast media. Table 7 Strategies to reduce the risk of contrast-induced acute kidney injury
Drugs
Hydration with isotonic saline [57] [58] [59] N-acetyl-cysteine [69, [106] [107] [108] [109] [110] Sodium bicarbonate [58, 68, 108, 109, 111] Theophylline [112] [113] [114] Mannitol [115] Furosemide [115] [116] [117] Ascorbic acid (vitamin C) [118] Tocopherol (vitamin E) [119] Statins [120] [121] [122] [123] [124] Mesna [125] Dopamine [126] Fenoldopam (dopamin agonist) [127] Calcium channel blockers (verapamil, diltiazem) [128] Adenosine [129] Endothelin receptor antagonists [130] Atrial natriuretic peptide [131] Iloprost (PGI2 analogue) [132] Misoprostol (PGE1 analogue) [133] Trimetazidine [134] Erythropoetin [135, 136] Nebivolol [137] Sodium citrate [138] Procedures Remote ischemic preconditioning [72, 73] Prophylactic hemodialysis/hemofiltration/hemodiafiltration [71, 139, 140] Ozkok S et al . Contrast-induced acute kidney injury sodium bicarbonate as protective against CIAKI [62, 63] while others found no beneficial effect [6466] . In a meta analysis, sodium bicarbonate was found to be protective against CIAKI but with a borderline significance [63] . In another 2 metaanalyses, no difference was found between bicarbonate and saline in terms of prevention from CIAKI [67, 68] . There is no standard dose of sodium bicarbonate for the prevention of CIAKI. In a study, bicarbonate solution was prepared by adding 154 mL of 1000 mEq/L sodium bicarbonate to 846 mL of 5% dextrose in H2O [62] . In this study, hydration with sodium bicarbonate before contrast exposure is more effective than hydration with sodium chloride for prophylaxis of CIAKI. In another study, bicarbonate solution was prepared with 75 mL of 8.4% sodium bicarbonate added to 1 L of isotonic saline [65] . In this study, no difference was found between sodium bicarbonate plus saline group and hyration with only saline group in terms of prevention from CI AKI. Since sodium bicarbonate contains high amount of sodium, risk of hypervolemia should be taken into consideration especially in patients with congestive heart failure and CKD and dose of the bicarbonate should be individualized.
N-acetylcysteine
Nacetylcysteine (NAC) did not decrease the risk of CIAKI in patients undergoing PTCA in a large rando mized trial [69] . There are several metaanalyses about the efficacy of NAC against CIAKI with both non significant [70] and significant results [67] . Although the strength of the evidence is low, NAC is a well tolerated, inexpensive drug and it has a relatively good profile of adverse effects. Thus, in 2012, KDIGO suggested NAC for patients with high risk of CIAKI [25] . There is no consensus on the dose of the NAC however it is usually used at a dose of 6001200 mg orally twice daily.
Prophylactic hemodialysis/hemofiltration
Prophylactic hemodialysis (HD) and hemofiltration (HF) were not found to be protective against CIAKI. In the metaanalysis including 8 studies of HD and 3 studies of HF, no beneficial effects of these treatment modalities was found against CIAKI [71] . Furthermore, HD was found to increase the risk of CIAKI. Thus prophylactic renal replacement treatments are not recommended.
Remote ischemic preconditioning
Remote ischemic preconditioning (RIP) is an interesting procedure that has been evaluated as a potential pro tective mechanism of CIAKI. RIP depends on a hypothesis that a transient ischemia of an organ may protect against an ischemic injury of another distant organ. Mostly, RIP has been induced by arm ischemia performed by inflation of blood pressure cuffs. In preliminary studies, RIP has been found to decrease the risk of CIAKI [72, 73] . However further randomized clinical trials are needed before a recommendation can be made.
Should we stop ACEI/ARB treatments before the contrast-enhanced imaging?
Some clinicians may prefer to stop angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) before the contrast administration because ACEI/ARB are considered to increase the risk of CIAKI. Supporting these concerns, in a retrospective study, use of ACEI/ARBs during PTCA was found to be independently associated with increased risk of CI AKI [74] . However in a prospective randomized trial, discontinuation of ACEI/ARB treatments 24 h before PTCA did not influence the incidence of CI-AKI in patients with CKD [75] . We think that, cessation of ACEI/ARB treatments for only 1 d before the procedure might not be adequate because renal hemodynamic effects of these drugs might last longer. In a very recent meta analysis, ACEI use was not found to have a significant effect on the CIAKI in patients undergoing PTCA [76] . In summary, there is not enough evidence to recommend withholding or continuing ACEI/ARB treatments before contrastenhanced imaging.
Should we stop metformin treatment before the contrast-enhanced imaging?
Metformin is not a nephrotoxic drug however it is excreted by the kidney. Metformin is known to cause severe lactic acidosis in patients with renal impairment. About 8% of cases reporting metformin induced lactic acidosis were found to be associated with CIAKI [77] . Cessation of metformin at least 48 h before the contrast admini stration is a common but controversial clinical practice [78] . According to other researchers, the risk of metformin induced lactic acidosis is extremely low in patients with normal renal function thus discontinuation of metformin is considered unnecessary in nonuremic patients [79] . We think that it will be appropriate to discontinue metformin especially in CKD patients who are planned to have a contrastenhanced procedure.
ALTERNATIVE NON-CONTRAST ENHANCED IMAGING TECHNIQUES
In the era of rapidly evolving technology, new noncontrast enhanced imaging modalities have been developed (Table  9 ). Most of these modalities are MRIbased techniques. Knowledge of these new techniques may be beneficial for the renal health of the patients needing contrast enhanced imaging and interventions. Preference of these imaging modalities may be discussed between the clini cian and radiologist.
CONTRAST USE IN END-STAGE RENAL
DISEASE
There are two concerns about the use of iodinated CM in patients with ESRD; risk of loss of residual renal function (RRF) and CMinduced hypervolemia.
Ozkok S et al . Contrast-induced acute kidney injury RRF is associated with better outcome and survival in patients with ESRD [80] . Thus it should be preserved by avoiding unnecessary use of CM and nephrotoxic drugs. HD treatment after iodinated CM exposure was not shown to preserve RRF in patients with ESRD [81] . Another concern about the contrast administration is the hypervolemia that may be induced by the CM. Sometimes clinicians may prefer to perform HD imme diately after contrast enhanced imaging. However as reported by Hamani et al [82] , new nonionic LOCM does not seem to increase serum osmolality, arterial blood pressure and it does not cause hypervolemia. Thus immediate HD may not be warranted to prevent hypervolemia in stable chronic HD patients.
GBCA should be better avoided in ESRD patients because of the risk of potentially mortal complication: NSF which is a systemic fibrosing disease that occurs due to exposure to GBCA especially in patients with GFR < 30 mL/min [83] . If it is inevitable to use GBCA in ESRD patients, immediate HD after the imaging procedure should be considered because GBCA has been shown to be effectively removed by HD [84] . However no proof exists that HD after GBCA exposure reduces the risk of NSF.
In HD patients without urine output (no RRF), if contrastenhanced imaging is required, CT is clearly preferred over MRI to avoid the risk of NSF.
PROGNOSIS OF CI-AKI
Short and long term mortalities of patients with CIAKI have been shown to be higher compared with patients without CIAKI [8587] . However there are few studies about the longterm renal prognosis of patients who developed CIAKI. In a prospective study performed on patients with symptomatic peripheral artery disease undergoing PTCA, patients with CIAKI were found to be at increased risk of longterm loss of renal function, cardiovascular events, and death [88] . In this study, one year after the procedure, decline in eGFR was significantly higher in patients with CIAKI compared with patients without CIAKI (12.4 mL/min vs 6.2 mL/min). In another observational study on CKD patients undergoing PTCA, persistent renal dysfunction was defined as the decrease of creatinine clearance ≥ 25% of baseline values at 3 mo [3] . In this study, overall incidence of CIAKI was found to be 12%, and persistent renal dysfunction was found in 18.6% of CIAKI patients. Similarly, in another study performed on patients undergoing PTCA, continuous deterioration of kidney function (CDKF) was defined as > 25% increase in serum creatinine or serum creatinine > 0.5 mg/dL above baseline at 6 to 8 mo after PTCA [4] . In this study CDFK was found in 16% of the study population and this group of patients was found to have significantly higher 5year mortality rate. In a large study performed to find the incidence of CKD onset after PTCA, incidence of newonset CKD within 6 mo of the procedure was found to be 0.9% [89] . Furthermore, in this study transradial access site was found to be associated with less CKD than the femoral approach.
CES
The most important alternative diagnosis of AKI after Ozkok S et al . Contrast-induced acute kidney injury contrastenhanced imaging especially PTCA is the CES which is rarer than CIAKI however longterm renal survival is significantly worse than CIAKI [90] . CES manifests later than CIAKI, usually 12 wk after the procedure. Dislodgement of cholesterol crystals from the atherosclerotic plaques leads to embolization of the small peripheral arterioles causing a multisystemic disease with allergicimmunological features including eosinophilia, hypocomplementemia, livedo reticularis, distal gan grenes with palpable pulses (bluetoe syndrome) and pathognomonic Hollenhorst plaques on ophthalmologic examination [91] . Renal biopsy reveals empty clefts within the obliterated lumens of the arterioles [90] . Differentia tion of CIAKI and CES is important because these two diseases may have different types of treatment modalities. Once developed, CIAKI necessitates only supportive measures. However since CES is a type of allergic immunological disease, antiinflammatory treatments such as corticosteroids and cyclophosphamide may be considered [92, 93] . But there is no proof of efficacy of these anti-inflammatory treatments on CES.
